Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.41 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945518 | 0.89 | HPGD (0.55) | HPGDALDH1A1CYP3A4ADORA2APDE4A | |
| SCHEMBL1944109 | 0.86 | HPGD (0.60) | HPGDALDH1A1CYP3A4ADORA2AADORA2B | |
| SCHEMBL2330664 | 0.86 | ALDH1A1 (0.47) | HPGDALDH1A1CYP3A4ADORA2AADORA2B | |
| SCHEMBL6305749 | 0.85 | ALDH1A1 (0.64) | HPGDALDH1A1CYP3A4ADORA2AADORA2B | |
| SCHEMBL22521702 | 0.83 | HPGD (0.57) | HPGDALDH1A1CYP3A4ADORA2BPDE4A | |
| SCHEMBL239409 | 0.83 | ALDH1A1 (0.45) | HPGDALDH1A1CYP3A4ADORA2AADORA2B | |
| SCHEMBL24559084 | 0.80 | HPGD (0.54) | HPGDALDH1A1CYP3A4ADORA2AADORA2B | |
| SCHEMBL1545990 | 0.78 | ALDH1A1 (0.75) | HPGDALDH1A1CYP3A4PDE4APDE4B | |
| SCHEMBL11606618 | 0.78 | ALDH1A1 (0.55) | HPGDALDH1A1CYP3A4PDE4APDE4B | |
| SCHEMBL22521705 | 0.77 | HPGD (0.54) | HPGDALDH1A1CYP3A4ADORA2BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8609671-B2 | Method of inhibiting hepatic fibrosis as a result of liver replacement or repair using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| EP-1789053-B1 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8188099-B2 | Method of decreasing hepatotoxic side effects using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-1444233-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | disclosed |
| EP-1444233-A2 | A 2B? ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-0383868-A4 | 1,3-UNSYMMETRICAL STRAIGHT CHAIN ALKYL-SUBSTITUTED 8-PHENYLXANTHINES | — | 1991-12-04 | — | — | EP | disclosed |
| US-5032593-A | Anithistamines | MARION MERRELL DOW INC. (US) | 1991-07-16 | — | — | US | disclosed |
| EP-0383868-A1 | 1,3-UNSYMMETRICAL STRAIGHT CHAIN ALKYL-SUBSTITUTED 8-PHENYLXANTHINES | MARION LABORATORIES, INC. (US) | 1990-08-29 | — | — | EP | disclosed |
| WO-1990000056-A1 | 1,3-UNSYMMETRICAL STRAIGHT CHAIN ALKYL-SUBSTITUTED 8-PHENYLXANTHINES | MARION LABORATORIES, INC. (US) | 1990-01-11 | — | — | WO | disclosed |
| US-4783530-A | CARDIOTONIC AND BRONCHODILATOR AGENTS | MARION LABORATORIES, INC. (US) | 1988-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | HPGD 810/4885ALDH1A1 156/4885CYP3A4 1398/4885 |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | HPGD 718/4885ALDH1A1 875/4885CYP3A4 1981/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | HPGD 899/4885ALDH1A1 691/4885CYP3A4 1327/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | HPGD 899/4885ALDH1A1 691/4885CYP3A4 1327/4885 |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | HPGD 810/4885ALDH1A1 156/4885CYP3A4 1398/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | HPGD 734/4885ALDH1A1 779/4885CYP3A4 925/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | HPGD 718/4885ALDH1A1 875/4885CYP3A4 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.